Acadian Asset Management LLC I Mab Transaction History

Acadian Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.21 - $1.9 $33,000 - $51,818	27,273 Added 21.26%	155,572 $295,000
Q3 2023 Nov 13, 2023	BUY	$1.18 - $3.06 $151,392 - $392,594	128,299 New	128,299 $168,000
Q2 2022 Aug 09, 2022	SELL	$8.27 - $18.43 $33,270 - $74,143	-4,023 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $50,448 - $188,799	4,023 New	4,023 $65,000
Q4 2021 Feb 10, 2022	SELL	$45.28 - $74.5 $1.91 Million - $3.14 Million	-42,214 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $9.86 Million - $14.6 Million	-172,360 Reduced 80.33%	42,214 $3.06 Million
Q2 2021 Aug 11, 2021	BUY	$47.86 - $83.95 $10.3 Million - $18 Million	214,574 New	214,574 $18 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $74.8M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.